Company Overview
PharmaCyte Biotech, Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry where it develops and prepares to commercialize cellular therapies for cancer utilizing live cell encapsulation technology in the United States. The company's proprietary approach, known as Cell-in-a-Box, relies on a cellulose-based system to advance its therapeutic candidates. Currently, the organization employs a workforce of just two individuals, reflecting a highly early-stage operational structure typical of research-focused biotechnology entities. With a market capitalization of $7.60M and no reported annual revenue, the company represents a micro-cap entity with minimal market penetration relative to established pharmaceutical peers. The absence of generated revenue combined with a small employee base indicates that the firm is in a development phase where capital is primarily directed toward research and development rather than commercialization or scaling operations.
Financial Health
The financial statements for PharmaCyte Biotech, Inc. show a Net Income of $-7,486,426 over the trailing twelve months, while revenue and EBITDA figures are not applicable due to the lack of commercial sales. The significant gap between the company's minimal revenue and its substantial negative net income reveals a cost structure heavily dominated by research and development expenses rather than the cost of goods sold or operating overhead associated with mature businesses. The company reports Free Cash Flow of $-1,694,738, indicating that it is burning cash to fund its scientific endeavors and does not yet possess the positive cash generation required to sustain operations without external capital. All three margin metrics—the Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet achieved profitability or generated sales volume sufficient to calculate meaningful margins. On the balance sheet, the company holds $20.54M in cash while debt figures are not applicable, suggesting a conservative financial posture reliant on cash reserves rather than leverage. The Debt to Equity ratio is not applicable, further confirming the absence of significant long-term debt obligations. Liquidity is extremely strong with a Current Ratio of 12.33, which indicates that the company possesses more than twelve times the current assets necessary to cover its short-term liabilities. However, the Return on Equity stands at -8.2% and the Return on Assets is -6.8%, metrics that reveal management is currently destroying shareholder value rather than generating returns, a common characteristic of pre-revenue biotechnology companies that have not yet successfully transitioned to the commercial phase.
Valuation Assessment
The valuation metrics for PharmaCyte Biotech, Inc. present a unique picture given the company's lack of earnings, with a Trailing P/E Ratio listed as N/A and a Forward P/E of -1.86. The negative forward P/E implies that the market is pricing in anticipated losses or that the company is not expected to generate positive earnings in the near future. The Price to Book ratio is 0.20, indicating that the company's market value is significantly below its book value, which often suggests either deep undervaluation or high perceived risk regarding the commercial viability of its pipeline. Alternative valuation metrics such as the Price to Sales ratio and EV/EBITDA are also N/A, reflecting the inability to value the company based on traditional revenue multiples or enterprise value multiples due to the absence of sales and EBITDA. The stock has exhibited volatility within a specific range, with a 52-Week High of $1.64 and a 52-Week Low of $0.63. Without the current price explicitly provided in the available facts, the trading position relative to the high and low cannot be numerically calculated, but the range demonstrates a total trading band of approximately $1.01 over the past year. The Beta is 0.43, which suggests that the stock's price volatility is less than 43% of the broader market's movement, indicating lower sensitivity to general market fluctuations compared to large-cap equities.
Growth & Income
Growth metrics for PharmaCyte Biotech, Inc. show Revenue Growth (YoY) and Earnings Growth (YoY) as N/A, as the company has not yet generated sufficient revenue to calculate year-over-year percentage changes. Consequently, there is no data to determine whether earnings are growing faster or slower than revenue, as both the numerator and denominator for these growth calculations are effectively zero or non-existent in a commercial sense. The company does not pay dividends, with a Dividend Yield of N/A and a Payout Ratio of 0.0%. Since the payout ratio is zero, the company is not distributing any earnings to shareholders, which is consistent with its status as a non-dividend payer that reinvests all available capital, including its $20.54M cash reserve, into research and development efforts rather than paying out income. The overall growth and income profile is characterized by a complete reliance on capital appreciation potential rather than dividend income or established revenue growth, positioning the asset strictly as a high-risk, high-potential developmental investment.